MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    A Systematic Review of the Type, Timing, Frequency and Durability of Effect in Parkinson’s Disease Physical Therapy

    M. El Hayek, J. Jofili Lopes, J. Lelaurin, A. Abi Nehme, K. Au, M. Okun, R. Salloum (Gainesville, USA)

    Objective: To evaluate all current evidence on the types, timing, frequency, duration, and outcomes of physical therapy (PT) regimens applied in Parkinson’s disease (PD). Background:…
  • 2023 International Congress

    Prevalence of cogwheel phenomenon in Parkinson disease

    S. Barua, W. Chouhani, A. D’Abreu, J. Friedman, U. Akbar (Providence, USA)

    Objective: To examine the prevalence of cogwheel rigidity (CWR) in a cohort of Parkinson disease (PD) patients Background: First noted in a 1901 publication, CWR…
  • 2023 International Congress

    Glucocerebrosidase (GCase) activator, Ambroxol, reduces alpha-synuclein serine-129 phosphorylation and oligomers in mutant LRRK2 R1441G mouse brains

    Z. Choi, E. Chang, H. Liu, S. Zhang, Y. Ruan, K. Leung, S. Pang, M. Kung, D. Ramsden, S. Ho, P. Ho (Hong Kong, Hong Kong)

    Objective: To explore whether inducing brain GCase activity by Ambroxol™ (ABX; a brain-penetrant GCase activator) can reduce a-synuclein (αSyn) serine-129 phosphorylation and oligomer accumulation in…
  • 2023 International Congress

    Functional circuit abnormalities in Levodopa-induced dyskinesia in Parkinson’s disease: A systematic review

    B. Thomsen, M. Vinding, D. Meder, L. Marner, A. Løkkegaard, H. Siebner (Hvidovre, Denmark)

    Objective: Levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD) are involuntary movements caused by long-term treatment with dopaminergic replacement therapy (levodopa). During the cause of PD,…
  • 2023 International Congress

    Frequency coding mechanism of tremor in the cerebellar circuitry

    MK. Pan, YM. Wang, CW. Liu, SY. Chen (Taipei, Taiwan)

    Objective: Tremor is an involuntary rhythmic movement. However, the frequency-coding mechanism of tremor remains unknown. This study aims to identify such mechanism in the central…
  • 2023 International Congress

    VALIdation of models for assessing eligibility for referral for Device-Aided Treatment in Parkinson’s disease (VALIDATE)

    H. Moes, E. Buskens, A. Portman, B. van Harten, M. van Kesteren, T. Mondria, L. Teune, E. van Wensen, M. van Onna, M. Schilperoord, A. Wertenbroek, M. Tjepkema-Cloostermans, L. Dorresteijn, T. van Laar (Groningen, Netherlands)

    Objective: To externally validate the Dutch Device-Aided Therapy Screening tool (D-DATS) and to compare it with the 5-2-1 criteria. Background: Timely identification of patients with…
  • 2023 International Congress

    Mosaic divergent repeat interruptions in X-linked dystonia-parkinsonism: stability over generations and time

    J. Laß, T. Lüth, K. Schlüter, RL. Rosales, RD. Jamora, G. Saranza, CCE. Diesta, S. Schaake, B. Laabs, N. Brüggemann, I. König, C. Klein, A. Westenberger, J. Trinh (Lübeck, Germany)

    Objective: This study aims to investigate the stability of Mosaic Divergent Repeat Interruptions affecting motif Length and Sequence (mDRILS) frequencies and repeat length across generations…
  • 2023 International Congress

    A novel, population-specific PINK1 p.F385S loss of function mutation in an Indian family with Parkinson’s disease

    K. Sharma, A. Kishore, A. Lechado, F. Raimondi, M. Sturm, A. Ashok-Kumar-Sreelatha, D. Kalikavil-Puthenveedu, G. Sarma, N. Casadei, R. Krüger, T. Gasser, P. Kahle, O. Riess, J. Fitzgerald, M. Sharma (Tübingen, Germany)

    Objective: To understand the molecular function of a novel missense PINK1 variant identified in an Indian family with Parkinson’s disease (PD). Background: The molecular understanding…
  • 2023 International Congress

    Sympathetic tone abnormalities in subjects at risk for Parkinson’s Disease without evidence of nigrostriatal neurodegeneration: a multimodal biomarker study

    M. Gregorio, H. Maghzi, G. Obialisi, E. Hogg, C. Malatt, E. Tan, H. Pomeroy, R. Artal, M. Shehata, B. Renner, P. Sati, G. Pagano, M. Tagliati (Los Angeles, USA)

    Objective: To study autonomic dysfunction in subjects with idiopathic REM sleep behavior disorder (iRBD) and at least one pre-motor symptom of Parkinson's disease (PD). Background:…
  • 2023 International Congress

    Testing gene-environment interaction in Parkinson’s disease (PD) using whole-genome sequencing of pesticide-exposed cohorts.

    S. Goldman, J. Kaye, M. Traglia, R. Swanson, L. Lima, S. Finkbeiner, C. Tanner (San Francisco, USA)

    Objective: To identify interactions of specific pesticides with genetic loci to find causal variants for PD using gene burden analysis (BA). Background: Pesticide exposure is…
  • « Previous Page
  • 1
  • …
  • 99
  • 100
  • 101
  • 102
  • 103
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24187 (not found)
  • #29526 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • “Striatal Hand Signs” and early diagnosis of Parkinson's Disease: The “Monkey-Wrench Sign”.
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley